Terence C Chua1, David L Morris. 1. Hepatobiliary and Surgical Oncology Unit, Department of Surgery, St George Hospital, University of New South Wales, Kogarah, NSW, 2217, Sydney, Australia. terence.chua@unsw.edu.au
Abstract
BACKGROUND: Hepatic resection is a potentially curative option for patients with colorectal liver metastases who are candidates for surgery. With the increasing availability of highly effective chemotherapy, surgery may be further advanced by the improved tumor response and better long-term outcomes associated with its use in the perioperative setting. METHODS: A commentary about the optimal timing of chemotherapy from the currently available evidence was performed. RESULTS: There is evidence to suggest that adjuvant chemotherapy after surgery for colorectal liver metastases improves disease-free and overall survival. The recent EORTC trial (40983) by Nordlinger and co-workers provides evidence for improved progression-free survival with the use of perioperative chemotherapy compared to surgery alone. CONCLUSION: Both adjuvant and perioperative chemotherapy appear to be beneficial over surgery alone for resectable colorectal liver metastases. Whether one is superior over the other remains unknown. Participation in ongoing trials to optimize the perioperative sequencing of chemotherapy would be important in identifying the optimal peri-surgical chemotherapy management of resectable colorectal liver metastases.
BACKGROUND: Hepatic resection is a potentially curative option for patients with colorectal liver metastases who are candidates for surgery. With the increasing availability of highly effective chemotherapy, surgery may be further advanced by the improved tumor response and better long-term outcomes associated with its use in the perioperative setting. METHODS: A commentary about the optimal timing of chemotherapy from the currently available evidence was performed. RESULTS: There is evidence to suggest that adjuvant chemotherapy after surgery for colorectal liver metastases improves disease-free and overall survival. The recent EORTC trial (40983) by Nordlinger and co-workers provides evidence for improved progression-free survival with the use of perioperative chemotherapy compared to surgery alone. CONCLUSION: Both adjuvant and perioperative chemotherapy appear to be beneficial over surgery alone for resectable colorectal liver metastases. Whether one is superior over the other remains unknown. Participation in ongoing trials to optimize the perioperative sequencing of chemotherapy would be important in identifying the optimal peri-surgical chemotherapy management of resectable colorectal liver metastases.
Authors: Rebecca C Auer; Rebekah R White; Nancy E Kemeny; Lawrence H Schwartz; Jinru Shia; Leslie H Blumgart; Ronald P Dematteo; Yuman Fong; William R Jarnagin; Michael I D'Angelica Journal: Cancer Date: 2010-03-15 Impact factor: 6.860
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey Journal: J Clin Oncol Date: 2008-10-20 Impact factor: 44.544
Authors: Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger Journal: Lancet Date: 2008-03-22 Impact factor: 79.321